Spermine, Iron, and the Longevity Paradox: A Molecule That Shields Cells From “Rusting to Death” — and Feeds Liver Cancer While Doing It
Researchers have identified spermine — a polyamine that the body makes from spermidine — as a natural iron chelator that directly grabs ferrous iron (Fe2+) and shuts down ferroptosis, an iron-driven form of cell death caused by runaway lipid peroxidation. In liver cancer, tumour cells exploit an unusual, glutamine-fuelled route (via the enzyme ALDH18A1) to overproduce spermine, starving the ferroptosis machinery of the free iron it needs and thereby protecting themselves from dying. Blocking this pathway kills tumours; supplementing spermine, by contrast, protects healthy organs from ischaemia–reperfusion (blood-flow-loss) injury. The same molecule is therefore protective in one context and pro-tumour in another.
For years, spermidine and its downstream cousin spermine have been longevity darlings — linked to autophagy, cardiovascular health, and extended lifespan in model organisms. A new paper in Nature complicates that story in an important way, and it does so with unusually rigorous biophysics.
The big idea is deceptively simple. Ferroptosis is a form of cell death that depends on iron: free Fe2+ catalyses the oxidation of membrane fats until the cell’s membranes fall apart. The team shows that spermine — uniquely among the common polyamines — carries four amino groups arranged so that it can wrap around a single iron atom and hold it, roughly one spermine to one iron. Putrescine (two amino groups) and spermidine (three) bind iron weakly or not at all. Spermine’s grip on Fe2+ is tight (dissociation constant about 4.4 micromolar) and thermodynamically favourable. By sequestering iron, spermine removes the spark that ignites lipid peroxidation, and the cell is protected from ferroptosis.
Cancer cells have learned to weaponise this. In two independent mouse models of hepatocellular carcinoma — the most common form of liver cancer — tumours ramp up spermine production through a non-canonical, glutamine-dependent pathway governed by the enzyme ALDH18A1. This lets them build spermine even when the usual arginine/ornithine supply is throttled. The payoff for the tumour is ferroptosis resistance. When the researchers disabled ALDH18A1 — genetically, with an AAV-delivered knockdown, or with an experimental small-molecule inhibitor called YG1702 — the tumour cells lost their iron shield, filled up with free Fe2+, peroxidised their own membranes, and died. Liver-cancer incidence in mice collapsed toward zero. Crucially, adding spermine back reversed the effect and let tumours grow again, confirming that spermine itself is the operative molecule.
The flip side is genuinely therapeutic. In healthy tissue that is briefly starved of blood and then re-perfused — as happens during transplant, stroke, heart attack, or surgery — ferroptosis drives much of the damage. Here, a low dose of injected spermine (1 mg/kg) markedly protected mouse liver, intestine, and kidney, lowering iron, lipid peroxidation, and clinical injury markers.
The take-home is a caution as much as a discovery: spermine’s cell-protective power is real and mechanistically explained, but “protecting cells from death” is exactly what you do not want in a pre-cancerous liver. Context, dose, and tissue matter enormously.
Actionable Insights (with effect sizes)
For a scientifically literate longevity audience, the single most important message is a directional warning that qualifies the popular spermidine/spermine longevity narrative, plus a narrower therapeutic signal.
- Spermine is context-dependent, not universally “good.” In these liver-cancer models, spermine is pro-tumour. Effect size (categorical, computed from the paper’s incidence tables): in the DEN/CCl4 model, dietary/supplemental spermine raised tumour incidence from 0/10 to 2/10 at 4 months and from 7/10 (70%) to 10/10 (100%) at 6 months. Hepatocyte-specific deletion of the spermine-building enzyme Aldh18a1 dropped tumour incidence from 70% to 0% (absolute risk reduction ~70 percentage points; relative risk ≈ 0 — essentially complete protection in this model). Anyone with elevated hepatocellular-carcinoma risk (cirrhosis, MASH/NASH, chronic hepatitis) should regard aggressive spermine/spermidine supplementation as an open question, not a settled benefit. [Confidence: Medium — strong in mice, unproven in humans]
- The mechanistic lever is iron, not autophagy, in this setting. Spermine binds Fe2+ with a dissociation constant of ~4.4 µM at ~1:1 stoichiometry (enthalpy ≈ −30 kJ/mol). This is the most transferable fact: spermine’s protective action here is chemical iron chelation, comparable in kind (if far weaker) to deferoxamine. [Confidence: High]
- Therapeutic niche: acute ischaemia–reperfusion. A single low dose of spermine (1 mg/kg i.p.) protected liver, gut, and kidney in mice, where tissue spermine exceeded local Fe2+ by more than 20-fold. This is a plausible acute-injury intervention (transplant, surgery), not a chronic longevity supplement rationale. [Confidence: Medium]
The honest net message: do not read this paper as “take more spermine to live longer.” Read it as “spermine controls a specific iron-death pathway, which is protective in acute injury but dangerous in a cancer-prone organ.”
Context / Source
- Paywalled Paper: Spermine is an endogenous iron chelator that inhibits ferroptosis.
- Journal: Nature, Vol. 655, 2 July 2026, pp. 240–249.
- Institutions / Countries: Lead and corresponding authorship centred at Sun Yat-sen University Cancer Center and Zhongshan School of Medicine, Sun Yat-sen University (Guangzhou, China); with UT Southwestern Medical Center (Dallas, USA), Institut Curie/CNRS/INSERM (Paris, France), and Université Paris Cité / Centre de Recherche des Cordeliers (Paris, France; Guido Kroemer’s group). Primary institution: China; genuinely multinational collaboration.
- Impact evaluation: Nature’s 2025 Journal Impact Factor is 56.1 (CiteScore 97.0). The impact score of this journal is 56.1, evaluated against a typical high-end range of 0–60+ for top general-science journals, therefore this is an Elite impact journal.